Virios Therapeutics, Inc. (VIRI)
| Previous close | 5.0700 |
| Open | 4.8600 |
| Bid | 4.3900 x 1200 |
| Ask | 5.0100 x 800 |
| Day's range | 4.4100 - 5.0050 |
| 52-week range | 3.3000 - 7.4500 |
| Volume | |
| Avg. volume | 20,566 |
| Market cap | 36.737M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0240 |
| Earnings date | 12 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.00 |
- Business Wire
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
ATLANTA, May 12, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022.
- Business Wire
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
ATLANTA, May 05, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and provide
- Business Wire
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for Fibromyalgia
ATLANTA, April 28, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 ("HSV-1")) study, which is a randomized, double-blind evaluation of IMC-1 in patients with fibr
